EUVIMEDEUVIMED entdecken
Open Access

Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans

Matthew J Klebanoff, Pengxiang Li, John K Lin, Jalpa A Doshi

JAMA · 2024

DOI: 10.1001/jama.2024.8917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Matthew J Klebanoff und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. Hauptthemen laut MEDLINE: Adalimumab, Biosimilar Pharmaceuticals, Formularies as Topic, Insurance Coverage. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study examines formulary coverage of brand-name adalimumab and biosimilars across Medicare Part D plans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabBiosimilar PharmaceuticalsFormularies as TopicInsurance CoverageMedicare Part DHumansDrugs, GenericUnited States

Substanzen

AdalimumabBiosimilar PharmaceuticalsDrugs, Generic

Autor:innen und Institutionen

  • Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
  • The University of Texas MD Anderson Cancer Center, Houston.

Förderung

  • NIA NIH HHS

Zitieren

APA

Klebanoff, M. J., Li, P., Lin, J. K., & Doshi, J. A. (2024). Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans. JAMA. https://doi.org/10.1001/jama.2024.8917

Vancouver

Klebanoff MJ, Li P, Lin JK, Doshi JA. Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans. JAMA. 2024. doi:10.1001/jama.2024.8917

BibTeX
@article{Klebanoff2024,
  author = {Klebanoff, Matthew J and Li, Pengxiang and Lin, John K and Doshi, Jalpa A},
  title = {Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.8917}
}
Kostenlos starten →